Genetic insights can
change everything


  • Coming soon: Invitae will launch patient-initiated testing in 2019. Sign up to learn more.
  • Not all genetic tests are created equal.Data sheds new light on non-clinical, direct-to-consumer tests.
  • Published in JCO: Guidelines miss ~45% of breast cancer patients with P/LP variants.Learn more.
  • Sponsored testing available through the Alnylam Act® Primary Hyperoxaluria Type 1 Program.Learn more.

Explore our genetic test catalog


Confirm a diagnosis, provide a better understanding of prognosis, and direct medical management

Learn more

Reproductive health

Help make healthy pregnancies possible with carrier screening and preimplantation testing

Learn more

Proactive health

Determine a healthy adult’s predisposition to cancer, cardiovascular conditions, and more

Learn more

The Invitae Network makes genetic information more powerful

The Invitae Network creates data-driven connections throughout the healthcare system to advance research and care.

  • Removes barriers to genetic testing to help patients receive an accurate diagnosis quicker
  • Provides information to researchers and biopharma companies to help bring new therapies to market sooner
  • Supports newly diagnosed patients and their clinicians in making decisions on next steps, including treatments, clinical trials, and research

Learn more

Transparent pricing. Ethical billing.


$250 patient pay

  • Diagnostic panels

  • Carrier screening

  • Proactive health (cancer or cardio)

A genetic diagnosis can affect an entire family

Only a small percentage of relatives pursue genetic testing after a disease-causing variant is found in their family, even though guidelines recommend it.1-3

Invitae now offers testing for all diagnostic and proactive panels to blood relatives at no additional charge* to help inform and empower more families. A discount is available for the Invitae Carrier Screen to all reproductive partners at a $100 patient-pay price.


*Order must be placed within 90 days of the original report

1. Christiaans I, et al. Update of genetic counseling and predictive DNA testing in hypertrophic cardiomyopathy. Eur J Hum Genet. 2008;16(10):1201-7.
2. Sharaf RN, et al. Uptake of genetic testing by relatives of Lynch syndrome probands: A systematic review. Clin Gastroenterol Hepatol. 2013;11(9):1093-100.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast and Ovarian V.2.2017. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed September 25, 2017. To view the most recent and complete version of the guideline, go online to  NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Stay in touch 

Join our mailing list to stay up to date on Invitae news, including publications, product updates, and new programs